ArticleThe Lancet. Oncology2019

Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.

Aung Naing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.